Edunn Biotechnology, Inc. ("Edunn") is developing a cure for Alzheimer's disease (AD) utilizing a nucleic acid that penetrates the blood-brain barrier targeting a specific protein known to affect the disease. Edunn is in preclinical development of a novel AD drug, a specific oligonucleotide or OL-1, that penetrates the blood-brain barrier and targets a mRNA for amyloid protein. Ol-1 has shown to be highly selective with significant activity and safety in multiple preclinical models. Ol-1 halts AD progression and reverses symptoms in animal models. OL-1 was invented by researchers at Saint Louis University Medical Center, led by Dr. John Morley.